Juan Pablo Cuello

Juan Pablo Cuello

Auto-generated profile, based on publicly available information

Juan Pablo Cuello

MS Unit, Neurology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2019 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
JCJ. P. Cuello
J. P. Cuello
MGM. L. Martínez Ginés
M. L. Martínez Ginés
JKJ. Kuhle
J. Kuhle
JDJose Manuel Garcia Dominguez
Jose Manuel Garcia Dominguez
ARA. Lozano Ros
A. Lozano Ros
LVLuisa Maria Villar
Luisa Maria Villar

1 March 2017 in Neurología
Verified
Journal Article
Open access
JCJ.P. Cuello
J.P. Cuello
MGM.L. Martínez Ginés
M.L. Martínez Ginés
MBM.L. Martin Barriga
M.L. Martin Barriga
CAC. de Andrés
C. de Andrés
Multiple sclerosis (MS) is a autoimmune disorder which preferentially affects young women of childbearing age. During pregnancy, the annualized relapse rate (AAR) is modified, but pregnancy has no harm effect on the long-term course of the disease. We aimed to study the clinical course of our MS patients during pregnancy, and compare their obstetrics outcomes with a control group of non-MS patients. A single centre prospective observational study was conducted. We assessed the reproductive history, MS history, pregnancy course and new-born outcome of a cohort of MS patients who had had a pregnancy between january 2007 and july 2012. We compared the global outcomes with a control cohort of 58 age-matched healthy pregnancies. Complete data from 35 consecutive women were analyzed, 40 deliveries. Control groups: 58 patients, 60 deliveries. EDSS at pregnancy 0,7. ARR before pregnancy 0,5. During pregnancy 0,3, after pregnancy 0,4. Twelve patients were on disease-modifying drugs (DMD) before pregnancy, 4 prenatal exposure occurs. The comparison between relapse rate and EDSS before, during and after delivery showed no statistically significant difference. In addition, compared to control group, there were also no differences in the obstetric outcomes. In MS cohort, we found a higher incidence of assisted reproductive treatments and lower breastfeeding rate, both statistically significant. Our series confirms that pregnancy has no negative long term impact on the progression of MS and also suggest that there is no additional morbidity in the pregnancy, comparing to the rest of the population.

18 October 2021 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
JCJuan Pablo Cuello
Juan Pablo Cuello
MGMaría Luisa Martínez Ginés
María Luisa Martínez Ginés
JDJosé Manuel García Domínguez
José Manuel García Domínguez
ATAmalia Tejeda‐Velarde
Amalia Tejeda‐Velarde
ARAlberto Lozano Ros
Alberto Lozano Ros
Roberto Álvarez-LafuenteRoberto Álvarez-Lafuente
Roberto Álvarez-Lafuente

1 July 2020 in Journal of the Neurological Sciences
Verified
Journal Article
Closed access
JCJuan Pablo Cuello
Juan Pablo Cuello
MGMaría Luisa Martínez Ginés
María Luisa Martínez Ginés
ATAmalia Tejeda-Velarde
Amalia Tejeda-Velarde
SHSilvia Medina Heras
Silvia Medina Heras
JDJosé Manuel García Domínguez
José Manuel García Domínguez
LVLuisa María Villar
Luisa María Villar

Verified
Journal Article
Open access
PDF file
EMEnric Monreal
Enric Monreal
JFJosé Ignacio Fernández-Velasco
José Ignacio Fernández-Velasco
SMSusana Sainz de la Maza
Susana Sainz de la Maza
MEMercedes Espiño
Mercedes Espiño
NVNOELIA VILLARRUBIA
NOELIA VILLARRUBIA
LVLuisa Maria Villar
Luisa Maria Villar
The combined use of serum and CSF biomarkers for prognostic stratification in multiple sclerosis (MS) remains underexplored. This multicenter observational study investigated associations between serum neurofilament light chain (sNfL), glial fibrillary acidic protein (sGFAP), and CSF lipid-specific IgM oligoclonal bands (LS-OCMB) with different forms of disability worsening, such as relapse-associated worsening (RAW), active progression independent of relapse activity (aPIRA), and non-active PIRA (naPIRA). A total of 535 patients with MS were included, all sampled within one year of disease onset. Biomarkers were quantified using single-molecule array and immunoblotting techniques, and CSF cell subsets were analyzed by flow cytometry. High sNfL z-scores and LS-OCMB positivity were independently associated with increased risk of RAW and aPIRA, collectively termed inflammatory-associated worsening (IAW), while elevated sGFAP levels predicted naPIRA. Patients with both high sNfL and LS-OCMB positivity had the highest risk of IAW. Among LS-OCMB–positive patients, higher regulatory T cell percentages were associated with lower sNfL levels, suggesting a protective role. Conversely, in LS-OCMB–negative patients, sNfL levels correlated with CSF C3 concentrations. These findings support the complementary role of sNfL, sGFAP, and LS-OCMB in identifying distinct mechanisms of disease worsening and may inform early personalized management strategies in MS.

6 March 2017 in Neurología (English Edition)
Verified
Journal Article
Open access
PDF file
JCJ.P. Cuello
J.P. Cuello
MGM.L. Martínez Ginés
M.L. Martínez Ginés
MBM.L. Martin Barriga
M.L. Martin Barriga
CAC. de Andrés
C. de Andrés
Introduction: Multiple sclerosis (MS) is a autoimmune disorder which preferentially affects young women of childbearing age. During pregnancy, the annualised relapse rate (AAR) is modified, but pregnancy has no harm effect on the long-term course of the disease. We aimed to study the clinical course of our MS patients during pregnancy, and compare their obstetrics outcomes with a control group of non-MS patients. Methods: A single centre prospective observational study was conducted. We assessed the reproductive history, MS history, pregnancy course and new-born outcome of a cohort of MS patients who had had a pregnancy between January 2007 and July 2012. We compared the global outcomes with a control cohort of 58 age-matched healthy pregnancies. Results: Complete data from 35 consecutive women were analysed, 40 deliveries. Control groups: 58 patients, 60 deliveries. EDSS at pregnancy 0.7. ARR before pregnancy 0.5. During pregnancy 0.3, after pregnancy 0.4. Twelve patients were on disease-modifying drugs (DMD) before pregnancy, 4 prenatal exposure occurs. The comparison between relapse rate and EDSS before, during and after delivery showed no statistically significant difference. In addition, compared to control group, there were also no differences in the obstetric outcomes. In MS cohort, we found a higher incidence of assisted reproductive treatments and lower breastfeeding rate, both statistically significant. Conclusions: Our series confirms that pregnancy has no negative long term impact on the progression of MS and also suggest that there is no additional morbidity in the pregnancy, comparing to the rest of the population. Introducción: La esclerosis múltiple (EM) es una enfermedad autoinmune que afecta preferentemente a mujeres en edad fértil. Durante el embarazo y puerperio, cambia la tasa anual de brotes (TAB) de EM, sin modificar la evolución a largo plazo. Analizamos la repercusión del embarazo en pacientes con EM, y comparamos sus resultados obstétricos con embarazos de mujeres sanas. Métodos: Estudio unicéntrico, observacional descriptivo, de diseño longitudinal prospectivo. Se analizan los datos globales de una cohorte de pacientes con EM que han dado a luz entre enero de 2007 y julio de 2012, con un seguimiento de 2 años posparto. Los resultados obstétricos se compararon con un grupo control de 58 embarazadas sanas, elegidas al azar de nuestro centro durante el mismo período de tiempo. Resultados: Un total de 35 pacientes con EM, 40 partos. Grupo control: 58 mujeres, 60 partos. EDSS preembarazo: 0,7. TAB 2 años preembarazo: 0,5. Durante el embarazo: 0,3, a los 2 años posparto: 0,4. Doce pacientes recibían FME previo al embarazo, 4 iniciaron la gestación con FME. No hubo diferencias estadísticamente significativas en la TAB ni en la EDSS entre períodos preembarazo, embarazo y posparto. Al comparar con grupo control, no hubo diferencias en edad materna, semanas de gestación, peso al nacer, porcentaje de cesáreas, ni complicaciones obstétricas. En pacientes con EM hubo mayor porcentaje de tratamientos por infertilidad y menor porcentaje de lactancia, ambos estadísticamente significativos. Conclusiones: Nuestro trabajo confirma que el embarazo no repercute negativamente en el curso de la EM y que no existe mayor morbilidad obstétrica comparado con mujeres sanas.